ORIC Pharmaceuticals (NASDAQ:ORIC) Given “Outperform” Rating at Wedbush

Wedbush reissued their outperform rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC) in a research report released on Thursday morning,RTT News reports. Wedbush currently has a $20.00 price target on the stock.

A number of other equities analysts have also recently weighed in on ORIC. Cantor Fitzgerald reissued an “overweight” rating on shares of ORIC Pharmaceuticals in a research note on Tuesday, January 14th. JPMorgan Chase & Co. boosted their price target on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a research note on Friday, February 21st. Finally, Guggenheim reissued a “buy” rating on shares of ORIC Pharmaceuticals in a research note on Wednesday, February 26th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $18.86.

ORIC Pharmaceuticals Price Performance

ORIC stock opened at $7.51 on Thursday. The firm has a market cap of $533.41 million, a PE ratio of -4.13 and a beta of 1.25. ORIC Pharmaceuticals has a 12 month low of $6.33 and a 12 month high of $15.35. The firm has a 50 day simple moving average of $9.09 and a 200 day simple moving average of $9.26.

ORIC Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.01. As a group, sell-side analysts expect that ORIC Pharmaceuticals will post -2.17 earnings per share for the current year.

Institutional Trading of ORIC Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ORIC. KLP Kapitalforvaltning AS acquired a new position in ORIC Pharmaceuticals in the 4th quarter worth about $50,000. BNP Paribas Financial Markets bought a new stake in shares of ORIC Pharmaceuticals in the 4th quarter valued at approximately $71,000. PNC Financial Services Group Inc. increased its holdings in ORIC Pharmaceuticals by 22.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company’s stock worth $109,000 after buying an additional 2,520 shares during the last quarter. Tower Research Capital LLC TRC raised its position in ORIC Pharmaceuticals by 1,048.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 14,661 shares of the company’s stock valued at $118,000 after acquiring an additional 13,384 shares in the last quarter. Finally, Janus Henderson Group PLC acquired a new stake in ORIC Pharmaceuticals in the fourth quarter valued at approximately $118,000. 95.05% of the stock is currently owned by hedge funds and other institutional investors.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.